The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence

Journal of Virology

Volumn 86, Issue 4, 2012, Pages 2323-2336

  Schweneker, Marc ^a   Lukassen, Susanne ^a   Späth, Michaela ^a   Wolferstätter, Michael ^a   Babel, Eveline ^a   Brinkmann, Kay ^a   Wielert, Ursula ^a   Chaplin, Paul ^a   Suter, Mark ^a,b   Hausmann, Jürgen ^a  

^a Bavarian Nordic GmbH   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C RAF PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; I KAPPA B ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; O1 PROTEIN; RAF PROTEIN; UNCLASSIFIED DRUG; VACCINIA VIRUS GROWTH FACTOR; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; C7L GENE; CELL CULTURE; CHORIOALLANTOIS VACCINIA VIRUS ANKARA; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXPERIMENTAL INFECTION; F17R GENE; FEMALE; GENE INSERTION; HUMAN; HUMAN CELL; LUNG; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; O1L GENE; OPEN READING FRAME; OVARY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; UPREGULATION; VACCINIA VIRUS; VGF GENE; VIRUS GENE; VIRUS INFECTION; VIRUS MUTANT; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; CELL LINE; ENZYME ACTIVATION; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; VACCINIA; VACCINIA VIRUS; VIRAL PROTEINS; VIRULENCE;

MAMMALIA; MUS; ORTHOPOXVIRUS; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

EID: 84857088609     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06166-11     Document Type: Article

References (69)

1. Andrade AA, et al. 2004. The vaccinia virus-stimulated mitogenactivated protein kinase (MAPK) pathway is required for virus multiplication. Biochem. J. 381:437-446.
2. Antoine G, Scheiflinger F, Dorner F, Falkner FG. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
3. Arakawa Y, Cordeiro JV, Schleich S, Newsome TP, Way M. 2007. The release of vaccinia virus from infected cells requires RhoA-mDia modulation of cortical actin. Cell Host Microbe 1:227-240.
4. Buller RM, Chakrabarti S, Cooper JA, Twardzik DR, Moss B. 1988. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J. Virol. 62:866-874.
5. Buller RM, Chakrabarti S, Moss B, Fredrickson T. 1988. Cell proliferative response to vaccinia virus is mediated by VGF. Virology 164:182-192.
6. Cai Y, Liu Y, Zhang X. 2007. Suppression of coronavirus replication by inhibition of the MEK signaling pathway. J. Virol. 81:446-456.
7. Caracciolo V, Reiss K, Khalili K, De Falco G, Giordano A. 2006. Role of the interaction between large T antigen and Rb family members in the oncogenicity of JC virus. Oncogene 25:5294-5301.
8. Carroll MW, Moss B. 1997. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238:198-211.
9. Chakrabarti S, Sisler JR, Moss B. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23:1094-1097.
10. Chen D, Waters SB, Holt KH, Pessin JE. 1996. SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J. Biol. Chem. 271:6328-6332.
11. Cooray S, et al. 2007. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J. Gen. Virol. 88:1656-1666.
12. Cudmore S, Cossart P, Griffiths G, Way M. 1995. Actin-based motility of vaccinia virus. Nature 378:636-638.
13. Dimier J, et al. 2011. Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice. J. Virol. 85:5016-5026.
14. Dougherty MK, et al. 2005. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17:215-224.
15. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:347-352.
16. Eblen ST, et al. 2004. Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol. Cell. Biol. 24:2308-2317.
17. Frischknecht F, et al. 1999. Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling. Nature 401:926-929.
18. Gedey R, Jin XL, Hinthong O, Shisler JL. 2006. Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells. J. Virol. 80:8676-8685.
19. Good MC, Zalatan JG, Lim WA. 2011. Scaffold proteins: hubs for controlling the flow of cellular information. Science 332:680-686.
20. Han MY, Kosako H, Watanabe T, Hattori S. 2007. Extracellular signalregulated kinase/mitogen-activated protein kinase regulates actin organization and cell motility by phosphorylating the actin cross-linking protein EPLIN. Mol. Cell. Biol. 27:8190-8204.
21. Hollinshead M, Rodger G, van Eijl H, Law M, Hollinshead R, Vaux DJ, Smith GL. 2001. Vaccinia virus utilizes microtubules for movement to the cell surface. J. Cell Biol. 154:389-402.
22. Hunger-Glaser I, Salazar EP, Sinnett-Smith J, Rozengurt E. 2003. Bombesin, lysophosphatidic acid, and epidermal growth factor rapidly stimulate focal adhesion kinase phosphorylation at Ser-910: requirement for ERK activation. J. Biol. Chem. 278:22631-22643.
23. Johnson RA, Ma XL, Yurochko AD, Huang ES. 2001. The role of MKK1/2 kinase activity in human cytomegalovirus infection. J. Gen. Virol. 82:493-497.
24. Kärber G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162:480-483.
25. Katz E, Ward BM, Weisberg AS, Moss B. 2003. Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein. J. Virol. 77:12266-12275.
26. Kennedy JS, Greenberg RN. 2009. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev. Vaccines 8:13-24.
27. Korotayev K, Chaussepied M, Ginsberg D. 2008. ERK activation is regulated by E2F1 and is essential for E2F1-induced S phase entry. Cell Signal. 20:1221-1226.
28. Langhammer S, Koban R, Yue C, Ellerbrok H. 2011. Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa). Antiviral Res. 89:64-70.
29. Ludwig S, et al. 2004. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett. 561:37-43.
30. Luo H, et al. 2002. Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J. Virol. 76:3365-3373.
31. Madshus IH, Stang E. 2009. Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking. J. Cell Sci. 122:3433-3439.
32. Marshall CJ. 1995. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185.
33. Martin S, Shisler JL. 2009. Early viral protein synthesis is necessary for NF-kappaB activation in modified vaccinia Ankara (MVA)-infected 293 T fibroblast cells. Virology 390:298-306.
34. Meisinger-Henschel C, et al. 2007. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J. Gen. Virol. 88:3249-3259.
35. Meisinger-Henschel C, et al. 2010. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice. J. Virol. 84:9907-9919.
36. Morales I, et al. 2008. The vaccinia virus F11L gene product facilitates cell detachment and promotes migration. Traffic 9:1283-1298.
37. Nguyen DH, et al. 1999. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J. Cell Biol. 146:149-164.
38. O'Connor M, Peifer M, Bender W. 1989. Construction of large DNA segments in Escherichia coli. Science 244:1307-1312.
39. Oie KL, Pickup DJ. 2001. Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappaB activation. Virology 288:175-187.
40. Opgenorth A, Nation N, Graham K, McFadden G. 1993. Transforming growth factor alpha, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits. Virology 192:701-709.
41. Planz O, Pleschka S, Ludwig S. 2001. MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells. J. Virol. 75:4871-4877.
42. Pleschka S, et al. 2001. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 3:301-305.
43. Postigo A, Martin MC, Dodding MP, Way M. 2009. Vaccinia-induced epidermal growth factor receptor-MEK signalling and the anti-apoptotic protein F1L synergize to suppress cell death during infection. Cell Microbiol. 11:1208-1218.
44. Ramos JW. 2008. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int. J. Biochem. Cell Biol. 40:2707-2719.
45. Rietdorf J, et al. 2001. Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus. Nat. Cell Biol. 3:992-1000.
46. Sancho MC, Schleich S, Griffiths G, Krijnse-Locker J. 2002. The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis. J. Virol. 76:8318-8334.
47. Seamone ME, et al. 2010. MAP kinase activation increases BK polyomavirus replication and facilitates viral propagation in vitro. J. Virol. Methods 170:21-29.
48. Shaul YD, Seger R. 2007. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim. Biophys. Acta 1773:1213-1226.
49. Shisler JL, Jin XL. 2004. The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. J. Virol. 78:3553-3560.
50. Spyropoulos DD, Stallard V, Roberts BE, Cohen LK. 1991. Utilization of DNA recombination for the two-step replacement of growth factor sequences in the vaccinia virus genome. J. Virol. 65:4609-4618.
51. Staib C, Drexler I, Sutter G. 2004. Construction and isolation of recombinant MVA. Methods Mol. Biol. 269:77-100.
52. Suter M, et al. 2009. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 27:7442-7450.
53. Sutter G, Moss B. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U. S. A. 89:10847-10851.
54. Sutter G, Staib C. 2003. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3:263-271.
55. Taylor JM, Barry M. 2006. Near death experiences: poxvirus regulation of apoptotic death. Virology 344:139-150.
56. Traverse S, et al. 1994. EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor. Curr. Biol. 4:694-701.
57. Tzahar E, et al. 1998. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 17:5948-5963.
58. Vial E, Pouyssegur J. 2004. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann. N. Y. Acad. Sci. 1030:208-218.
59. Vial E, Sahai E, Marshall CJ. 2003. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4:67-79.
60. von Krempelhuber A, et al. 2010. A randomized, double-blind, dosefinding phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 28:1209-1216.
61. Wang F, Barrett JW, Ma Y, Dekaban GA, McFadden G. 2009. Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized. J. Virol. 83: 5928-5932.
62. Wang F, et al. 2004. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol. 5:1266-1274.
63. Ward BM, Moss B. 2001. Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera. J. Virol. 75:4802-4813.
64. Wolffe EJ, Weisberg AS, Moss B. 1998. Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread. Virology 244:20-26.
65. Xing Z, Cardona CJ, Anunciacion J, Adams S, Dao N. 2010. Roles of the ERK MAPK in the regulation of proinflammatory and apoptotic responses in chicken macrophages infected with H9N2 avian influenza virus. J. Gen. Virol. 91:343-351.
66. Yoon S, Seger R. 2006. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24:21-44.
67. Zhang H, et al. 2010. Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2. Virus Res. 150:22-27.
68. Zhang WH, Wilcock D, Smith GL. 2000. Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence. J. Virol. 74:11654-11662.
69. Zwang Y, Yarden Y. 2009. Systems biology of growth factor-induced receptor endocytosis. Traffic 10:349-363.